

Angelica L Quartino

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7268928/publications.pdf>

Version: 2024-02-01

24
papers

786
citations

623574

14
h-index

580701

25
g-index

25
all docs

25
docs citations

25
times ranked

1028
citing authors

#	ARTICLE	IF	CITATIONS
1	ABBY. <i>Neurology</i> , 2018, 90, e1889-e1897.	1.5	188
2	Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE). <i>Alzheimer's Research and Therapy</i> , 2018, 10, 96.	3.0	109
3	Population pharmacokinetics of bevacizumab in cancer patients with external validation. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 341-351.	1.1	52
4	Population pharmacokinetic and exposure-response analysis for trastuzumab administered using a subcutaneous manual syringe injection or intravenously in women with HER2-positive early breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 77-88.	1.1	52
5	Population pharmacokinetic and covariate analysis of pertuzumab, a HER2-targeted monoclonal antibody, and evaluation of a fixed, non-weight-based dose in patients with a variety of solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 819-829.	1.1	50
6	Characterization of Endogenous G-CSF and the Inverse Correlation to Chemotherapy-Induced Neutropenia in Patients with Breast Cancer Using Population Modeling. <i>Pharmaceutical Research</i> , 2014, 31, 3390-3403.	1.7	45
7	Bevacizumab dosing strategy in paediatric cancer patients based on population pharmacokinetic analysis with external validation. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 148-160.	1.1	38
8	Safety, Tolerability, and Pharmacokinetics of Crenezumab in Patients with Mild-to-Moderate Alzheimer's Disease Treated with Escalating Doses for up to 133 Weeks. <i>Journal of Alzheimer's Disease</i> , 2020, 76, 967-979.	1.2	36
9	Pharmacokinetics and pharmacodynamic effect of crenezumab on plasma and cerebrospinal fluid beta-amyloid in patients with mild-to-moderate Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 16.	3.0	31
10	Pharmacokinetic and exposure-response analyses of pertuzumab in combination with trastuzumab and docetaxel during neoadjuvant treatment of HER2+ early breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 353-361.	1.1	21
11	Population pharmacokinetic and covariate analyses of intravenous trastuzumab (Herceptin®), a HER2-targeted monoclonal antibody, in patients with a variety of solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 329-340.	1.1	21
12	Inverse relationship between leukaemic cell burden and plasma concentrations of daunorubicin in patients with acute myeloid leukaemia. <i>British Journal of Clinical Pharmacology</i> , 2011, 71, 514-521.	1.1	18
13	Population pharmacokinetics and exposure-response of trastuzumab emtansine in advanced breast cancer previously treated with HER2-targeted regimens. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 2767-2777.	1.1	18
14	Exposure-response analyses of trastuzumab emtansine in patients with HER2-positive advanced breast cancer previously treated with trastuzumab and a taxane. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 1079-1090.	1.1	17
15	Population pharmacokinetic and pharmacodynamic analysis of plasma $A\hat{I}^2 ₄₀$ and $A\hat{I}^2 ₄₂$ following single oral doses of the BACE1 inhibitor AZD3839 to healthy volunteers. <i>Clinical Pharmacology in Drug Development</i> , 2014, 3, 396-405.	0.8	13
16	Prediction and Modeling of Effects on the QTc Interval for Clinical Safety Margin Assessment, Based on Single-Ascending-Dose Study Data with AZD3839. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2014, 350, 469-478.	1.3	13
17	A Pharmacometric Analysis of Patient-Reported Outcomes in Breast Cancer Patients Through Item Response Theory. <i>Pharmaceutical Research</i> , 2018, 35, 122.	1.7	13
18	The risk of febrile neutropenia in breast cancer patients following adjuvant chemotherapy is predicted by the time course of interleukin-6 and C-reactive protein by modelling. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 490-500.	1.1	12

#	ARTICLE	IF	CITATIONS
19	Modeling of In Vitro Drug Activity and Prediction of Clinical Outcome in Acute Myeloid Leukemia. <i>Journal of Clinical Pharmacology</i> , 2007, 47, 1014-1021.	1.0	11
20	Translational and pharmacokinetic-pharmacodynamic application for the clinical development of GDC-0334, a novel TRPA1 inhibitor. <i>Clinical and Translational Science</i> , 2021, 14, 1945-1954.	1.5	8
21	Safety, Tolerability, and Pharmacokinetics of High-Volume Subcutaneous Crenezumab, With and Without Recombinant Human Hyaluronidase in Healthy Volunteers. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 1337-1348.	2.3	6
22	Mechanistic Modeling of Soluble A β Dynamics and Target Engagement in the Brain by Anti-A β mAbs in Alzheimer's Disease. <i>Current Alzheimer Research</i> , 2020, 17, 393-406.	0.7	6
23	Population pharmacokinetic and exploratory exposure-response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 88, 499-512.	1.1	4
24	Pharmacokinetics of trastuzumab emtansine (T-DM1) as a single agent or in combination with pertuzumab in HER2-positive breast cancer patients with recurrent or locally advanced metastatic breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 175-185.	1.1	3